Lloyd Stahl, MD
Cardiovascular Disease · Overland Park, KSNPI 1326098492
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 86 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for cardiovascular disease clinicians in KS, where the typical reported total is $2,383.
Across 86 payments — averaging $18.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Irhythm Technologies, Inc.$246
- Johnson & Johnson$231
- Pfizer$219
- Boston Scientific$144
- Amgen$109
- Sanofi-aventis U.S. LLC$100
- plus $541 from 14 others
Across 37 payments — averaging $7411.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$135K
- Eli Lilly$79K
- Boehringer Ingelheim$50K
- Novartis$10K
- Boehringer Ingelheim Canada Ltd.ltee$321
- Boehringer Ingelheim France S.a.s.$255
What the payments were for
- Food & beverage$1,591100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Irhythm Technologies, Inc. | 11 | $246 |
| Johnson & Johnson | 14 | $231 |
| Pfizer | 16 | $219 |
| Boston Scientific | 7 | $144 |
| Amgen | 7 | $109 |
| Sanofi-aventis U.S. LLC | 7 | $100 |
| Abbott | 1 | $97 |
| Novo Nordisk | 4 | $85 |
| AstraZeneca | 4 | $69 |
| Astellas Pharma US Inc | 2 | $47 |
| E.r. Squibb & Sons, L.L.C. | 2 | $45 |
| Philips North America LLC | 3 | $43 |
| Lemaitre Vascular, Inc. | 1 | $43 |
| Lundbeck LLC | 1 | $19 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Vital Connect, Inc | 1 | $16 |
| Medtronic | 1 | $15 |
| Novartis | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
How this compares
$1,591 in reported general payments places this provider in the 40th percentile of 175 cardiovascular disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 143 | $157,974 |
| XareltoRivaroxaban | 110 | $129,242 |
| JardianceEmpagliflozin | 57 | $55,494 |
| EntrestoSacubitril/Valsartan | 47 | $54,776 |
| Repatha SureclickEvolocumab | 30 | $27,110 |
| NexlizetBempedoic Acid/Ezetimibe | 26 | $18,106 |
| Flecainide Acetate | 135 | $5,302 |
| Rosuvastatin Calcium | 188 | $3,599 |
| Atorvastatin Calcium | 239 | $2,755 |
| Losartan Potassium | 250 | $2,689 |
| Metoprolol Succinate | 164 | $1,957 |
| Carvedilol | 169 | $1,706 |
| SotalolSotalol Hcl | 33 | $877 |
| Potassium Chloride | 35 | $874 |
| Amlodipine Besylate | 126 | $831 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $219 | $157,974143 claims |
| Johnson & JohnsonXarelto | $231 | $129,242110 claims |
| NovartisEntresto | $15 | $54,77647 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 175 cardiovascular disease providers in Kansas.
Other cardiovascular disease in Overland Park
- Vasvi SinghOverland Park$405K
- Rachel SoslandOverland Park$33K
- Ahmed ElballatOverland Park$22K
- Paul NagerOverland Park$10K
- Ronnie SmallingOverland Park$9K
- van JonesOverland Park$7K
- Alan SchneiderOverland Park$6K
- Theodore PopeOverland Park$5K
- Stephen BloomOverland Park$5K
- James MarcumOverland Park$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.